News from IIR members: Sofrigam

The number of drugs (e.g. targeted therapies, new vaccines, anti-diabetic drugs and blood derivatives) transported and kept at a controlled temperature is growing rapidly and these products are increasingly sensitive to temperature variations. In order to ensure zero risk (deterioration of the main active ingredients during transport and external handling, health risk for patients, loss of control by the original manufacturer, etc.), these products require "intelligent" packaging that is often tailor-made. An understanding of the regulatory environment on national and international levels is essential. For this reason, Sofrigam supported the 1st round table 2008 "Pharmaceutical distribution, how to preserve the quality of the cold chain" held in May 2008.